DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Current Liabilities
All obligations due within one year.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 23.2% from a year ago
Total current liabilities stood at $5.75M at the end of Q1 FY2026, up 23.2% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at +33.3% a year.
Context
- Total current liabilities amounted to 10.8% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +23.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.13M USD
- Year-over-year change
- -4.8%
- 4-year CAGR
- +35.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.13M | -4.8% |
| FY2024 | 2024-12-31 | 5.39M | +93.5% |
| FY2023 | 2023-12-31 | 2.79M | +28.5% |
| FY2022 | 2022-12-31 | 2.17M | +42.3% |
| FY2021 | 2021-12-31 | 1.52M | — |
Total Current Liabilities vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total current liabilities of $5.75M is the lowest of the 7 companies compared; the peer median is $26.21M.
- Its year-over-year change of +23.2% is the 3rd highest of 7, against a peer median of +6.5%.
- Total current liabilities amounts to 10.8% of total assets for DMAC, versus a peer median of 8.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $173.88M | +90.6% | +7.9% | 48.0% | |
| Jun 2026 | $90.08M | -1.1% | -35.3% | 7.8% | |
| Mar 2026 | $26.49M | +58.8% | +79.3% | 41.1% | |
| Mar 2026 | $25.93M | -21.0% | +41.4% | 8.9% | |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $15.83M | -33.3% | +50.9% | 4.0% |
| Mar 2026 | $5.75M | +23.2% | +33.3% | 10.8% | |
| Peer median (excluding DMAC) | $26.21M | +6.5% | +24.7% | 8.3% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.